WallStSmart
TVTX

Travere Therapeutics Inc

NASDAQ: TVTX · HEALTHCARE · BIOTECHNOLOGY

$40.10
-1.93% today

Updated 2026-04-29

Market cap
$3.70B
P/E ratio
P/S ratio
7.55x
EPS (TTM)
$-0.57
Dividend yield
52W range
$14 – $43
Volume
1.9M

Travere Therapeutics Inc (TVTX) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+133.2%
Last 4 quarters
Revenue YoY growth
+73.4%
Most recent quarter
EPS YoY growth
+178.7%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+8.6%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+17.3%
2025-10-30
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-19$0.37+1025.0%$27.87$30.39+9.0%
2025-10-30$0.59+303.4%$29.98$35.16+17.3%
2025-07-30$0.13+147.9%$15.53$15.45-0.5%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.04$0.37+1025.0%$129.69M+73.4%
2025-09-30$-0.29$0.59+303.4%$164.86M+162.1%
2025-06-30$-0.27$0.13+147.9%$114.45M+111.5%
2025-03-31$-0.39$-0.19+51.8%$81.73M+97.5%
2024-12-31$-0.38$-0.47-24.1%$74.79M+66.0%
2024-09-30$-0.68$-0.70-2.9%$62.90M+69.6%
2024-06-30$-0.86$-0.91-5.8%$54.12M+68.1%
2024-03-31$-0.99$-1.76-77.8%$41.37M
2023-12-31$-1.27$-1.18+7.1%$45.06M
2023-09-30$-0.14$-1.17-735.7%$37.09M
2023-06-30$-1.16$-1.13+2.6%$32.20M

Frequently asked questions

Has Travere Therapeutics Inc beaten earnings estimates?
Travere Therapeutics Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +133.2% over the last 3 quarters.
How does TVTX stock react to earnings?
TVTX stock has moved an average of +8.6% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Travere Therapeutics Inc's revenue growth rate?
Travere Therapeutics Inc reported year-over-year revenue growth of +73.4% in its most recent quarter, with EPS growing +178.7% year-over-year.